Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 1—January 2009


Sphingomonas paucimobilis Bloodstream Infections Associated with Contaminated Intravenous Fentanyl1

CME Logo

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME for physicians. Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at; (4) view/print certificate.

Learning Objectives

• Upon completion of this activity, participants will be able to:

• Describe the types of bacterial contamination associated with different compounding pharmacy medications.

• Describe the features of Sphingomonas paucimobilis bacteria.

• Identify the types of exposure associated with transmission of S. paucimobilis infection with contaminated fentanyl.

• Describe a strategy that would limit the occurrence of compounding pharmacy product contamination.


Lynne Stockton, Copy Editor, Emerging Infectious Diseases. Disclosure: Lynne Stockton has disclosed no relevant financial relationships.


Désirée Lie, MD, MSEd, Clinical Professor, Family Medicine, University of California, Orange; Director, Division of Faculty Development, UCI Medical Center, Orange, California. Disclosure: Désirée Lie, MD, MSEd, has disclosed no relevant financial relationships.


Disclosures: Lisa L. Maragakis, MD, MPH; Romanee Chaiwarith, MD, MHS; Arjun Srinivasan, MD; Francesca J. Torriani, MD, FIDSA; Edina Avdic, PharmD; Andrew Lee, BS, MPH; and Tracy R. Ross, BS, have disclosed no relevant financial relationships. Karen C. Carroll, MD, has disclosed that she has received grants for clinical support from BD GeneOhm, Prodesse, MicroPhage, and has served as an advisor or consultant to Boehringer Ingelheim and OpGen. Trish M. Perl, MD, MSc, has disclosed that she has received grants for clinical research from 3M and Sage and has served as an advisor or consultant to 3M, TheraDoc, and GlaxoSmithKline. Dr. Perl has also disclosed that she has served on the data monitoring board for Cadence.


Article Navigation